An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

Trial Profile

An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Anti-PSCA monoclonal antibody (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Agensys
  • Most Recent Events

    • 10 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 29 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Oct 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top